home · filing · 0001437749-25-001949
8-K filed January 28, 2025, 6:59 PM ET
ticker VXRT
CIK 0000072444
leadership
confidence high
sentiment neutral
materiality 0.50
Vaxart appoints Kevin Finney to board; Robert Yedid resigns
Vaxart, Inc.
Kevin Finney appointed to Vaxart board effective Jan 28, 2025; will serve on Audit and Nominating/Governance committees.
Robert A. Yedid resigned from board on Jan 28, 2025 for personal reasons; no disagreement with the company.
Elaine J. Heron appointed to Compensation Committee effective Jan 28, 2025.
Finney is CEO/President of Autobahn Therapeutics and brings 35 years of biotech leadership experience.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Departed
Robert A. Yedid
Director
Effective 2025-01-28
Filed January 28, 2025, 6:59 PM ET
Robert A. Yedid resigned from the Board and any committees of the Board, effective January 28, 2025
Appointed
Kevin Finney
Director
Effective 2025-01-28
Filed January 28, 2025, 6:59 PM ET
the Board appointed Kevin Finney to serve on the Board, effective January 28, 2025
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert A. Yedid resigned as Director at Vaxart, Inc..
Action resigned
Role Director
Exact text from the filing
Robert A. Yedid resigned from the Board and any committees of the Board, effective January 28, 2025
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kevin Finney was appointed as Director at Vaxart, Inc..
Action appointed
Role Director
Exact text from the filing
the Board appointed Kevin Finney to serve on the Board, effective January 28, 2025
View on SEC.gov
Source: SEC EDGAR
accession 0001437749-25-001949
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.